Head-to-head · WeighScore
FMmeds vs Nucific
The verdict
FMmeds takes it — 63.2/100 to 56.2/100.
FMmeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FMmeds is a Manhattan Beach-based DTC telehealth platform selling compounded semaglutide and tirzepatide co-formulated with vitamin B12, with no membership fee and a free initial visit billed only on approval.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FMmeds | Nucific |
|---|---|---|
| WeighScore | 63.2/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #257 | #417 |
| Semaglutide | $225/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $265/mo (all doses, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #257 · C
Strengths
- All 50 states plus DC covered, stated in the Terms
- Operating LLC and full Manhattan Beach, CA address disclosed
- Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
- Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
- Flat pricing across all dose strengths — no dose-escalation surcharge
Where it loses points
- Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
- Clinical network not separately named
- LegitScript Certified, but the specific ID isn't shown
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.